Circle
Circle
Circle
Cube
CircleCircle
Circle
CircleCircle
Shapes

News & Views

At Enveda, we are tackling the toughest challenges in drug discovery, finding and developing new compounds from the expanse of the natural world.

Subscribe to follow our progress.

Subscribe
Subscribed successfully!
Oops! Something went wrong while submitting the form.

Highlights

06/14/2024

Enveda raises $55M to combine ancient remedies with AI for drug discovery

Enveda announced that it has raised a $55 million Series B2 from new investors, including Microsoft, The Nature Conservancy, Premji Invest and Lingotto

Read more

05/30/2024

Enveda translates life’s chemistry into medicines

By learning from life’s chemistry, Enveda aims to solve the toughest challenges facing human and planetary health.

Read more

5/29/2024

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

Enveda announces a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM

Read more

05/28/2024

PRISM: A foundation model for life’s chemistry

Enveda’s PRISM (Pretrained Representations Informed by Spectral Masking) model was trained on 1.2 billion small molecule mass spectra

Read more

04/22/2024

A Healthy Planet for Healthy People

The biotechnology industry works tirelessly to develop new medicines and technologies that improve outcomes for patients

Read more

10/12/2023

Preserving Humanity and Our Medicines Relies on Conserving Our Planet’s Biodiversity Now

Enveda’s Knowledge Graph is the world’s largest computable database of ethnobotany, including 38,000 plants, 11,000 diseases and more than 20,000,000

Read more

10/05/2023

Rediscovering Therapeutic Roots: How Ethnobotany Aids Drug Discovery

Our goal at Enveda is to crack this code by creating technologies that can do for life’s chemistry what Next Generation Sequencing did for genomics

Read more

09/28/2023

The Chemical Code: An Opportunity Bigger Than The Genetic Code

It is as if we sequenced the genome and forgot everything else happening within the cell.

Read more

06/21/2023

Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

The algorithm, MS2Mol, powers Enveda’s drug discovery platform which finds new medicines in nature with unprecedented speed

Read more

6/20/2023

MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature

In many ways, life is chemistry. Metabolism, DNA replication, cell division, all of life's essential processes are – at their most essential – a series of chemi

Read more

05/08/2023

Enveda Selected to Present Latest Work in Natural Language Processing at ICLR 2023

Multi-scale Sinusoidal Embeddings Enable Learning on High Resolution Mass Spectrometry Data

Read more

04/20/2023

Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

New investor Kinnevik led the round with outsized participation from current investors. The company is advancing multiple candidates toward the clinic

Read more

03/08/2023

Inspirational Women of Enveda

We asked eight of Enveda's inspirational women to tell us about their role and what they'd tell their younger self about it

Read more

02/22/2023

GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra

The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed

Read more

02/15/2023

Enveda's matured platform drives toward three INDs in 2023

CEO Viswa Colluru believes Enveda has found the answer in a platform that combines metabolomics and ML to predict unknown chemistry at unprecedented accuracy

Read more

12/21/2022

Enveda closes $68-million combined Series B equity and debt financing

Round included multiple new institutional investors and all its current major investors

Read more

11/11/2022

TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data

The core problem in natural product drug discovery: finding needles in nature’s haystack.

Read more

News

Show all

Enveda raises $55M to combine ancient remedies with AI for drug discovery

Enveda announced that it has raised a $55 million Series B2 from new investors, including Microsoft, The Nature Conservancy, Premji Invest and Lingotto

Enveda translates life’s chemistry into medicines

By learning from life’s chemistry, Enveda aims to solve the toughest challenges facing human and planetary health.

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

Enveda announces a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM

PRISM: A foundation model for life’s chemistry

Enveda’s PRISM (Pretrained Representations Informed by Spectral Masking) model was trained on 1.2 billion small molecule mass spectra

A Healthy Planet for Healthy People

The biotechnology industry works tirelessly to develop new medicines and technologies that improve outcomes for patients

Preserving Humanity and Our Medicines Relies on Conserving Our Planet’s Biodiversity Now

Enveda’s Knowledge Graph is the world’s largest computable database of ethnobotany, including 38,000 plants, 11,000 diseases and more than 20,000,000

Rediscovering Therapeutic Roots: How Ethnobotany Aids Drug Discovery

Our goal at Enveda is to crack this code by creating technologies that can do for life’s chemistry what Next Generation Sequencing did for genomics

The Chemical Code: An Opportunity Bigger Than The Genetic Code

It is as if we sequenced the genome and forgot everything else happening within the cell.

Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

The algorithm, MS2Mol, powers Enveda’s drug discovery platform which finds new medicines in nature with unprecedented speed

MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature

In many ways, life is chemistry. Metabolism, DNA replication, cell division, all of life's essential processes are – at their most essential – a series of chemi

Enveda Selected to Present Latest Work in Natural Language Processing at ICLR 2023

Multi-scale Sinusoidal Embeddings Enable Learning on High Resolution Mass Spectrometry Data

Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

New investor Kinnevik led the round with outsized participation from current investors. The company is advancing multiple candidates toward the clinic

Inspirational Women of Enveda

We asked eight of Enveda's inspirational women to tell us about their role and what they'd tell their younger self about it

GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra

The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed

Enveda's matured platform drives toward three INDs in 2023

CEO Viswa Colluru believes Enveda has found the answer in a platform that combines metabolomics and ML to predict unknown chemistry at unprecedented accuracy

Searching for Medicine’s Answers in the Most Powerful Library on Earth

“We started Enveda to build the first high-resolution chemical map of planet Earth and change where we look for new medicines."

'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023

Enveda will enter the clinic next year with at least one of three main programs

Enveda closes $68-million combined Series B equity and debt financing

Round included multiple new institutional investors and all its current major investors

TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data

The core problem in natural product drug discovery: finding needles in nature’s haystack.

Natural Products in Protein Degradation: Past, Present, and Future

Protein degradation, whether as a PROTAC (proteolysis targeting chimera) or a molecular glue, is an emerging new modality of therapeutic action...

Enveda Biosciences to Open Advanced Drug Discovery and Development Center in Boulder, Colo.; Lead Optimization Laboratory in Hyderabad, Telangana, India

Enveda Biosciences to Open Advanced Drug Discovery and Development Center in Boulder, Colo.; Lead Optimization Laboratory in Hyderabad, Telangana, India...

Enveda Biosciences Adds Drug Development Leaders to Scale Efforts and Accelerate Progress

New team members deepen Enveda’s global drug development expertise as its therapeutics pipeline expands and advances...

A Recursion veteran is mapping plant life to chart a course to new therapies — and investors like what they see

One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving...

Lux Capital Leads $51 Million Financing in Biotech Startup Enveda - Company searches for compounds from nature to develop medications

Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped...

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announc...

Exploiting the Therapeutic Potential of Plants

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of...

Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database

Enveda Bioscienes has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biologi...

Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics

Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures...

Why we invested in Enveda

In the Spring of 2018, one of our LPs based in Salt Lake City introduced me to a founder named Dan Wee from the vibrant bioscience community there...

Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation

It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound...

Mass spectrometry searches using MASST

Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query...

Global chemical effects of the microbiome include new bile-acid conjugations

A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes...

Celebrating the departure of an outstanding employee

A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion...

Arrow leftArrow right

Blog

Show all

PRISM: A foundation model for life’s chemistry

Enveda’s PRISM (Pretrained Representations Informed by Spectral Masking) model was trained on 1.2 billion small molecule mass spec

A Healthy Planet for Healthy People

The biotechnology industry works tirelessly to develop new medicines and technologies that improve outcomes for patients

Preserving Humanity and Our Medicines Relies on Conserving Our Planet’s Biodiversity Now

Enveda’s Knowledge Graph is the world’s largest computable database of ethnobotany, including 38,000 plants, 11,000 diseases

Rediscovering Therapeutic Roots: How Ethnobotany Aids Drug Discovery

Our goal at Enveda is to crack this code by creating technologies that can do for life’s chemistry what Next Generation Sequencing

The Chemical Code: An Opportunity Bigger Than The Genetic Code

Chemistry links all life more intimately than genetics.

MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature

This is a continuation of a series of blogs on teaching computers the language of chemistry

Inspirational Women of Enveda

We asked inspiring Enveda women to tell us about their roles and what they'd tell their younger self about that their journey

GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra

The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed

Natural Products as Drugs: Evolution as Master Medicinal Chemist

Where are the richest caches of “drug-like” molecules?

Machine Learning will Revolutionize Metabolomics

Metabolomics is a rapidly emerging field that seeks to measure the landscape of metabolites, or organic small molecules, in liv...

Fulfilling the Promise of Natural Products with Technology: Discovering the Next Generation of Small Molecules

In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four mole...

Drug Discovery Productivity at Enveda —Biotech Innovation with Big Pharma Efficiency

Once the initial project goals are defined, biologists build assays that can reproducibly evaluate compounds (agonists, antagon...

Artemisinins, Malaria, and The Quest to Systematize Collaboration between Nature and Scientists (Cures and Nobel Prizes)

Mother Nature is, by far, the most accomplished drug discovery researcher in the history of the world, in spite of the fact..

Arrow leftArrow right

Subscribe To Follow Our Progress.

Subscribed successfully!
Oops! Something went wrong while submitting the form.